Multicenter Retrospective Study of Xenotransfusion of Canine Plasma Products to Cats: 14 Cases (2022-2024).

Canine plasma xenotransfusion in cats is potentially life-saving but requires careful safety monitoring.

This multicenter retrospective study examined 14 cats that received 16 canine plasma xenotransfusions between 2022-2024 across one university teaching hospital and two private referral centers. Indications included confirmed coagulopathy (7 cases), suspected coagulopathy (1 case), oncotic support (5 cases), and severe hypovolemia (1 case). Of six coagulopathic cats, three achieved normalization of both PT and aPTT post-transfusion. Median volume administered was 11.35 mL/kg over 3.9 hours. Six cats received canine plasma exclusively, with two (33.3%) experiencing suspected acute transfusion reactions manifesting as acute respiratory distress. Overall outcomes showed 35.7% survived to discharge, 42.9% were euthanized, and 21.4% experienced cardiopulmonary arrest. The study concludes that canine plasma xenotransfusion may serve as a life-saving alternative when feline plasma is unavailable for treating coagulopathies and providing colloidal support, though the safety profile requires further investigation.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.